Filing Flows › Editas Medicine (EDIT) › Q3 2026
Editas Medicine (EDIT) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 9, 2026
Editas Medicine (EDIT) reported revenue of $10.4M for the third quarter 2026 (Q3 2026), +37% from a year earlier and -13% from the quarter before. Operating margin was -234.3%, net loss $23.4M (225.7% of revenue).
Editas Medicine, Q3 2026: revenue $10.4M (+37% year over year), operating margin -234.3%, net loss $23.4M, operating cash flow −$21.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.4M | -13% | +37% |
| Operating profit | −$24.3M | — | — |
| Net earnings | −$23.4M | — | — |
| Operating cash flow | −$21.2M | — | — |
What changed
Revenue was $10.4M in Q3 2026, up 37% year over year and down 13% from the previous quarter.
Operating costs exceeded revenue by $24.3M, an operating margin of -234.3%. Total costs grew 8% against revenue growth of 37%. The quarter ended with a net loss of $23.4M, wider than the previous quarter's $18.2M loss.
Operating cash flow was −$21.2M. Non-cash charges added back $385K of depreciation and $2.6M of share-based compensation.
Questions
What was Editas Medicine's revenue in the third quarter 2026?
Editas Medicine (EDIT) reported revenue of $10.4M for the third quarter 2026 (Q3 2026), +37% from a year earlier and -13% from the quarter before.
Was Editas Medicine profitable in the third quarter 2026?
Operating loss was $24.3M (-234.3% of revenue) and net loss $23.4M.
Source: Editas Medicine 10-Q on SEC EDGAR.